Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE-CODA: Contezolid and Delamanid Short Regimen for RR-TB
NCT06081361Phase 3Active, not recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of contezolid in Tuberculosis (TB) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Favourable outcome rate at 24 months after randomization. Started Dec 2023; status: active, not recruiting.
02
Drugs
contezolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06081361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081361.